Advertisement

CNS Drugs

, Volume 20, Issue 2, pp 125–141 | Cite as

Hormone-Related Headache

Pathophysiology and Treatment
  • Avi Ashkenazi
  • Stephen D. Silberstein
Therapy In Practice

Abstract

Epidemiological data suggest a link between migraine and the female sex hormones. Indeed, it is known that estrogen affects various brain functions, including pain perception. The prevalence of migraine is similar in boys and girls before puberty, but is 3-fold higher in postpubertal females compared with males. Migraine attacks in women are more likely to occur in the perimenstrual period and occur exclusively so in some women. The acute treatment of menstrual migraine is similar to that of non-menstrually related attacks, but the response to treatment may be less favourable. Perimenstrual prophylaxis, with NSAIDs, triptans or estradiol, is effective in decreasing attack frequency and severity.

The use of oral contraceptives (OCs) may change migraine frequency and severity. Since both migraine and hormonal contraceptive use are risk factors for ischaemic stroke, the use of OCs in women who experience migraine should be made only after consideration of the benefit-risk ratio.

Migraine typically, but not invariably, improves during the last two trimesters of pregnancy, and may worsen in the postpartum period. When using drugs to treat migraine during pregnancy, potential risks to the mother and fetus should be considered.

The prevalence of migraine decreases with advancing age and it improves in many, but not all, women after the menopause. However, in the perimenopausal period, migraine may worsen as a result of fluctuations in estrogen levels. Reducing the estrogen dose and changing the estrogen type or the route of administration of hormone replacement therapy (HRT) from oral to transdermal may reduce headache. Migraine is not a risk factor for stroke in postmenopausal women. When considering symptomatic HRT for postmenopausal migraneurs, the usual indications and contraindications should be applied. HRT may also exacerbate migraine.

Keywords

Migraine Hormone Replacement Therapy Sumatriptan Migraine Attack Migraine With Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Dr Ashkenazi has received research support from and served as a speaker to Merck. Dr Silberstein is on the advisory panel, speakers’ bureau or serves as a consultant for Abbott, AGA, Allergan, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Medtronics, Merck, Pfizer and Pozen. He receives research support from Abbott, Advanced NeuroModulation Systems, Allergan, AstraZeneca, Eisai, Endo, Johnson & Johnson, Lilly, GlaxoSmithKline, OrthoMcNeil, Medtronics, Merck, NPS, Pfizer, Pozen, UCB Pharma and X-Cel Pharmaceuticals. No funding was used to assist in the preparation of this manuscript. The authors would like to thank Mrs Linda Algarin Kelly and Mrs Lynne Kaiser for their professional work in helping bring this manuscript to print.

References

  1. 1.
    Silberstein SD, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology 1999; 53: S3–13PubMedCrossRefGoogle Scholar
  2. 2.
    Silberstein SD, DeLignieres B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000; 20: 214–21PubMedCrossRefGoogle Scholar
  3. 3.
    Abu-Arefeh I, Russell G. Prevalence of headache and migraine in school children. BMJ 1994; 309: 765–9PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–9PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart WF, Linet MS, Celentano DD, et al. Age and sexspecific incidence rates of migraine with and without visual aura. Am J Epidemiol 1991; 34: 1111–20Google Scholar
  6. 6.
    Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–57PubMedCrossRefGoogle Scholar
  7. 7.
    McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20: 279–307PubMedCrossRefGoogle Scholar
  8. 8.
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618–29PubMedCrossRefGoogle Scholar
  9. 9.
    Stomati M, Bernardi F, Luisi S, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and beta-endorphin. Maturitas 2002; 43: 195–206PubMedCrossRefGoogle Scholar
  10. 10.
    Headache Classification Committee. The international classification of headache disorders. 2nd ed. Cephalalgia 2004; 24: 1–160Google Scholar
  11. 11.
    MacGregor EA, Chia H, Vohrah RC, et al. Migraine and menstruation: a pilot study. Cephalalgia 1990; 10: 305–10PubMedCrossRefGoogle Scholar
  12. 12.
    Cupini LM, Matteis M, Troisi E, et al. Sex-hormone related events in migrainous females: a clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995; 15: 140–4PubMedCrossRefGoogle Scholar
  13. 13.
    MacGregor EA, Igarashi H, Wilkinson M. Headaches and hormones: subjective versus objective assessment. Headache Quarterly 1997; 8: 126–36Google Scholar
  14. 14.
    Johannes CB, Linet MS, Stewart WF, et al. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology 1995; 45: 1076–82PubMedCrossRefGoogle Scholar
  15. 15.
    Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000; 55: 1517–23PubMedCrossRefGoogle Scholar
  16. 16.
    MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004; 63: 351–3PubMedCrossRefGoogle Scholar
  17. 17.
    Keenan PA, Lindamer LA. Nonmigraine headache across the menstrual cycle in women with and without premenstrual syndrome. Cephalalgia 1992; 12: 356–9PubMedCrossRefGoogle Scholar
  18. 18.
    Somerville BW. Estrogen-withdrawal migraine: I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975; 25: 239–44Google Scholar
  19. 19.
    Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972; 22: 355–65PubMedCrossRefGoogle Scholar
  20. 20.
    Biegon A, Reches A, Snyder L, et al. Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormones. Life Sci 1983; 32: 2015–28PubMedCrossRefGoogle Scholar
  21. 21.
    Genazzani AR, Petraglia F, Volpe A, et al. Estrogen changes as a critical factor in modulation of central opioid tonus: possible correlations with postmenopausal migraine. Cephalalgia 1985; 2: 211–4Google Scholar
  22. 22.
    Boyle CA. Management of menstrual migraine. Neurology 1999; 53: S14–18PubMedGoogle Scholar
  23. 23.
    Facchinetti F, Neri I, Martignoni E, et al. The association of menstrual migraine with the premenstrual syndrome. Cephalalgia 1993; 13: 422–5PubMedCrossRefGoogle Scholar
  24. 24.
    Nattero G, Allais G, DeLorenzo C, et al. Relevance of prostaglandins in true menstrual migraine. Headache 1989; 29: 233–8PubMedCrossRefGoogle Scholar
  25. 25.
    Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004; 24: 707–16PubMedCrossRefGoogle Scholar
  26. 26.
    Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003; 23: 302–8PubMedCrossRefGoogle Scholar
  27. 27.
    Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the nonprescription of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin Ther 1999; 21: 475–91PubMedCrossRefGoogle Scholar
  28. 28.
    Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993; 82: 769–72PubMedGoogle Scholar
  29. 29.
    Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. 017 Clinical Trial Study Group. Neurology 1997; 49: 1210–8Google Scholar
  30. 30.
    Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, doubleblind, placebo-controlled study. Headache 2004; 44: 120–30PubMedCrossRefGoogle Scholar
  31. 31.
    Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998; 51: 307–9PubMedCrossRefGoogle Scholar
  32. 32.
    Newman LC, Mannix LK, Landy SH, et al. Naratriptan as shortterm prophylaxis for menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2000; 41: 248–56CrossRefGoogle Scholar
  33. 33.
    Nett R, Mannix LK, Landy S, et al. A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg twice daily as prophylactic treatment for menstrually-associated migraine [abstract]. Neurology 2003; 60(5): A95Google Scholar
  34. 34.
    Silberstein SD, Elkind AH, Schreiber C, et al. Randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63: 261–9PubMedCrossRefGoogle Scholar
  35. 35.
    Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30: 705–9PubMedCrossRefGoogle Scholar
  36. 36.
    de Lignières B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous estradiol [letter]. BMJ 1986; 293: 1540PubMedCrossRefGoogle Scholar
  37. 37.
    Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2: 113–20PubMedCrossRefGoogle Scholar
  38. 38.
    Ferrante F, Fusco E, Calabresi P, et al. Phyto-oestrogens in the prophylaxis of menstrual migraine. Clin Neuropharmacol 2004; 27: 137–40PubMedCrossRefGoogle Scholar
  39. 39.
    Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist an d“add-back” therapy. Fertil Steril 1997; 67: 390–3PubMedCrossRefGoogle Scholar
  40. 40.
    Martin V, Wernke S, Mandell K, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003; 43: 309–21PubMedCrossRefGoogle Scholar
  41. 41.
    Larrson-Cohn U, Lundberg PO. Headache and treatment with oral contraceptives. Acta Neurol Scand 1970; 46: 267–78CrossRefGoogle Scholar
  42. 42.
    Bassol S, Alvarado A, Celis C, et al. Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/ 150 microg desogestrel. Contraception 2000; 62: 131–5PubMedCrossRefGoogle Scholar
  43. 43.
    Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001 Jun; 63(6): 297–302PubMedCrossRefGoogle Scholar
  44. 44.
    Martinez-Manautou J. Continuous low dose progestagen for contraception. IPPF Med Bull 1968; 2: 2–3PubMedGoogle Scholar
  45. 45.
    Anonymous. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2: bleeding patterns and side effects. Contraception dy1978; 17: 35-406Google Scholar
  46. 46.
    Potter LS, Dalberth BT, Canamar R, et al. Depot medroxyprogesterone acetate pioneers: a retrospective study at a North Carolina Health Department. Contraception 1997; 56: 305–12PubMedCrossRefGoogle Scholar
  47. 47.
    Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63–74PubMedCrossRefGoogle Scholar
  48. 48.
    Crosby UD, Schwarz BE, Gluck KL, et al. A preliminary report of Norplant implant insertions in a large urban family planning program. Contraception 1993; 48: 359–66PubMedCrossRefGoogle Scholar
  49. 49.
    Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3: 85–91PubMedCrossRefGoogle Scholar
  50. 50.
    Edwards JE, Moore A. Implanon: a review of clinical studies. Br J Fam Plann 1999; 24: 3–16PubMedGoogle Scholar
  51. 51.
    Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiologic study in 1300 women. Headache 1993; 33: 385–9PubMedCrossRefGoogle Scholar
  52. 52.
    Mueller L. Predictability of exogenous hormone effect on subgroups of migraineurs. Headache 2000; 40: 189–93PubMedCrossRefGoogle Scholar
  53. 53.
    Kelman L. Women’s issues of migraine in tertiary care. Headache 2004; 44: 2–7PubMedCrossRefGoogle Scholar
  54. 54.
    Bousser MG. Estrogens, migraine, and stroke. Stroke 2004; 35: 2652–6PubMedCrossRefGoogle Scholar
  55. 55.
    Tzourio C, Iglesias S, Hubert JB, et al. Migraine and risk of ischemic stroke: a case-control study. BMJ 1993; 307: 289–92PubMedCrossRefGoogle Scholar
  56. 56.
    Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischemic stroke in young women. BMJ 1995; 310: 830–3PubMedCrossRefGoogle Scholar
  57. 57.
    Carolei A, Marini C, DeMatteis G, et al. History of migraine and risk of cerebral ischaemia in young adults. Lancet 1996; 343: 1503–6Google Scholar
  58. 58.
    Merikangas KR, Fenton B, Cheng SH, et al. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997; 54: 362–8PubMedCrossRefGoogle Scholar
  59. 59.
    Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318: 13–8Google Scholar
  60. 60.
    Donaghy M, Chang CL, Poulter N. On behalf of the European Collaborators of the World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 2002; 73: 747–50Google Scholar
  61. 61.
    Kruit MD, vanBuchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 921: 427–34CrossRefGoogle Scholar
  62. 62.
    Tzourio C, Kittner SJ, Bousser MG, et al. Migraine and stroke in young women. Cephalalgia 2000; 20: 190–9PubMedCrossRefGoogle Scholar
  63. 63.
    Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62: 1399–401PubMedCrossRefGoogle Scholar
  64. 64.
    Lidegaard O. Oral contraceptives, pregnancy, and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine, and previous thrombotic disease. Br J Obstet Gynaecol 1995; 102: 153–9PubMedCrossRefGoogle Scholar
  65. 65.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischemic stroke and combined oral contraceptives: results of an international, multicenter, case-control study. Lancet 1996; 348: 498–505CrossRefGoogle Scholar
  66. 66.
    Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202–8PubMedCrossRefGoogle Scholar
  67. 67.
    Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96PubMedCrossRefGoogle Scholar
  68. 68.
    Bousser MG, Kittner SJ. Oral contraceptives and stroke. Cephalalgia 2000; 20: 183–9PubMedCrossRefGoogle Scholar
  69. 69.
    Siritho S, Thrift AG, McNeil JJ, et al. Risk of ischemic stroke among users of the oral contraceptive pill: the Melbourne Risk Factor Study (MERFS) Group. Stroke 2003; 34: 1575–80PubMedCrossRefGoogle Scholar
  70. 70.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception 1998; 57: 315–24CrossRefGoogle Scholar
  71. 71.
    Heinemann LA, Assman A, Dominh T, et al. Oral progestogenonly contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67–73PubMedCrossRefGoogle Scholar
  72. 72.
    Martinelli IC, Sacchi E, Landi G, et al. High risk of cerebralvein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793–7PubMedCrossRefGoogle Scholar
  73. 73.
    Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453–7PubMedCrossRefGoogle Scholar
  74. 74.
    Becker WJ. Use of oral contraceptives in patients with migraine. Neurology 1999; 53: 519–25Google Scholar
  75. 75.
    World Health Organization. Medical eligibility criteria for contraceptive use. World Health Organization: Geneva: 2004Google Scholar
  76. 76.
    ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions. Number 18, July 2000. Int J Gynaecol Obstet 2001; 75: 93–106Google Scholar
  77. 77.
    Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task orce on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia 2000; 20: 155–6Google Scholar
  78. 78.
    Silberstein SD. Headaches in pregnancy. Neurol Clin 2004; 22: 727–56PubMedCrossRefGoogle Scholar
  79. 79.
    Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during preganancy and postpartum. Headache 1999 Oct; 39(9): 625–32PubMedCrossRefGoogle Scholar
  80. 80.
    Maggioni F, Alessi C, Maggino T, et al. Headache during pregnancy. Cephalalgia 1997; 17: 765–9PubMedCrossRefGoogle Scholar
  81. 81.
    Ratinahirana H, Darbois Y, Bousser MG. Migraine and pregnancy: a prospective study in 703 women after delivery [abstract]. Neurology 1990; 40: 437Google Scholar
  82. 82.
    Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23: 197–205PubMedCrossRefGoogle Scholar
  83. 83.
    Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology 1991; 41: 775–93CrossRefGoogle Scholar
  84. 84.
    Chancellor AM, Wroe SJ, Cull RE. Migraine occurring for the first time in pregnancy. Headache 1990 Mar; 30(4): 224–7PubMedCrossRefGoogle Scholar
  85. 85.
    Stein GS. Headaches in the first postpartum week and their relationship to migraine. Headache 1981; 21: 201–5PubMedCrossRefGoogle Scholar
  86. 86.
    Ponder TM. Differential diagnosis of postdural puncture headache in the parturient. Clin Forum Nurse Anesthetists 1999; 10: 145–54Google Scholar
  87. 87.
    Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20–4PubMedCrossRefGoogle Scholar
  88. 88.
    Warner G. Relaxation therapy in migraine and chronic tension headache. Med J Aust 1975; 1: 298–301PubMedGoogle Scholar
  89. 89.
    Scharff L, Marcus DA, Turk DC. Maintenance of effects in the nonmedical treatment of headaches during pregnancy. Headache 1996; 36: 285–90PubMedCrossRefGoogle Scholar
  90. 90.
    McCrory DC, Matchar DB, Ashenasi A, et al. Migraine: a module for the Physician Information and Education Resource (PIER), 2004 [online]. Available from URL: http://pier.acponline.org/index.html [Accessed 2005 Dec 10]
  91. 91.
    Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159–63PubMedCrossRefGoogle Scholar
  92. 92.
    Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. Headache 1999; 40: 20–4CrossRefGoogle Scholar
  93. 93.
    Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351–6PubMedCrossRefGoogle Scholar
  94. 94.
    Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17: 1–7PubMedCrossRefGoogle Scholar
  95. 95.
    Dey R, Khan S, Akhouri V, et al. Labetalol for prophylactic treatment of intractable migraine during pregnancy. Headache 2002; 42: 642–5PubMedCrossRefGoogle Scholar
  96. 96.
    d’Amato CC, Pizza V, Giordano E, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999 Nov–Dec; 39(10): 716–9PubMedCrossRefGoogle Scholar
  97. 97.
    MacGregor EA, Barnes D. Migraine in a specialist menopause clinic. Climacteric 1999; 2: 218–23PubMedCrossRefGoogle Scholar
  98. 98.
    Fettes I. Migraine in the menopause. Neurology 1999; 53Suppl. 1: S29–33PubMedGoogle Scholar
  99. 99.
    Neri I, Granella F, Nappi RMGC, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17: 31–7PubMedCrossRefGoogle Scholar
  100. 100.
    Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during enopausal transition. Headache 2003; 43: 470–8PubMedCrossRefGoogle Scholar
  101. 101.
    Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 2003; 12: 1027–36CrossRefGoogle Scholar
  102. 102.
    MacGregor A. Estrogen replacement and migraine aura. Headache 1999; 39: 674–8PubMedCrossRefGoogle Scholar
  103. 103.
    Nappi RE, Cagnacci A, Granella F, et al. Course of primary eadaches during hormone replacement therapy. Maturitas 2001; 38: 157–63PubMedCrossRefGoogle Scholar
  104. 104.
    Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002; 42: 924–9PubMedCrossRefGoogle Scholar
  105. 105.
    MacGregor A. Effects of oral and transdermal estrogen replacement on migraine. Cephalalgia 1999; 19: 124–5PubMedCrossRefGoogle Scholar
  106. 106.
    Ficicioglu C, Gurbuz B, Tasdemir S, et al. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004; 18: 240–3PubMedCrossRefGoogle Scholar
  107. 107.
    Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996 Aug 15; 335(7): 453–61PubMedCrossRefGoogle Scholar
  108. 108.
    Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75PubMedCrossRefGoogle Scholar
  109. 109.
    Kittner SJ, Bousser MG. Postmenopausal hormone replacement therapy and stroke risk. Cephalalgia 2000; 20: 208–13PubMedCrossRefGoogle Scholar
  110. 110.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33CrossRefGoogle Scholar
  111. 111.
    Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839–54PubMedCrossRefGoogle Scholar
  112. 112.
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12PubMedCrossRefGoogle Scholar
  113. 113.
    Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804PubMedCrossRefGoogle Scholar
  114. 114.
    Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349: 535–45PubMedCrossRefGoogle Scholar
  115. 115.
    Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003; 348: 579–80PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of NeurologyThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations